Oxular is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
Oxular’s significant innovation is the combination of:
- tissue-specific delivery of potent drug products that address the significant pathophysiological pathways of retinal disease
- treatment durability that safely provides up to 12-months of treatment effects from a single administration
Oxular utilizes its technology across its pipeline to develop treatments for retinal diseases, such as diabetic macular edema and macular degeneration, as well as programs for rare and orphan conditions, including ocular cancers and delivery of gene therapies.
Click on the images below for an introduction to Oxular’s technology.